Procarta Biosciences Ltd.

https://www.procartabio.com

Procarta Biosystems, a UK-based company, is developing a pipeline of antibacterials from its Oligonucleotide Antimicrobial platform, a novel nanoparticle approach targeting a new class of antibiotics targets, transcription factors. Its lead asset, PRO-202, is in preclinical development to treat complicated urinary tract infections (cUTI) and complicated intraabdominal infections (cIAI). *

	Start	2019-01-21 existent
	Industry	antibiotic
	Industry 2	PRO-202 (Procarta Biosystems)

	Region	Norwich, Norfolk
	Country	United Kingdom (GB)
	City	NR4 7UH Norwich, Norfolk
	Tel	+44-1603-456500
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Novo Holdings A/S. (1/21/19). "Press Release: Novo Holdings Announces New Investments by REPAIR Impact Fund. Four Investments Nade in First Year, Totalling €18 Million". Copenhagen.

		Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Procarta Biosciences Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)